Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + daclatasvir versus ribavirin in severe COVID-19
IRCT20200324046850N2Phase 2Completed
- Sponsor
- Abadan University of Medical Sciences
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of sofosbuvir, daclatasvir and ribavirin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Abadan University of Medical Sciences. Primary endpoints: Level of consciousness, Respiratory rate and 6 more. Started Mar 2020; status: completed.
02
Drugs
sofosbuvirdaclatasvirribavirin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200324046850N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200324046850N2.